{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:42:56Z","timestamp":1792096976081,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.jns.2012.12.013","type":"journal-article","created":{"date-parts":[[2013,1,5]],"date-time":"2013-01-05T15:18:56Z","timestamp":1357399136000},"page":"50-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Immunotherapy against amyloid pathology in Alzheimer's disease"],"prefix":"10.1016","volume":"333","author":[{"given":"Daniela","family":"Galimberti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Scarpini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2012.12.013_bb0005","doi-asserted-by":"crossref","first-page":"470S","DOI":"10.1093\/ajcn\/83.2.470S","article-title":"Inflammation and neurodegenerative diseases","volume":"3","author":"Griffin","year":"2006","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.jns.2012.12.013_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1874609810801010030","article-title":"Inflammation in neurodegenerative disorders: friend or foe?","volume":"1","author":"Galimberti","year":"2008","journal-title":"Curr Aging Sci"},{"issue":"4","key":"10.1016\/j.jns.2012.12.013_bb0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3233\/JAD-2009-1013","article-title":"Oxidative stress in diabetes and Alzheimer's disease","volume":"16","author":"Reddy","year":"2009","journal-title":"J Alzheimers Dis"},{"issue":"2\u20133","key":"10.1016\/j.jns.2012.12.013_bb0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-2006-102-303","article-title":"Metals and Alzheimer's disease","volume":"10","author":"Adlard","year":"2006","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.jns.2012.12.013_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/156720509787313899","article-title":"Cholesterol in Alzheimer's disease: unresolved questions","volume":"6","author":"Stefani","year":"2009","journal-title":"Curr Alzheimer Res"},{"issue":"5","key":"10.1016\/j.jns.2012.12.013_bb0030","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/A:1022419712453","article-title":"The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems","volume":"23","author":"Lawrence","year":"1998","journal-title":"Neurochem Res"},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2012.12.013_bb0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S1041610203008688","article-title":"A clinical overview of cholinesterase inhibitors in Alzheimer's disease","volume":"14","author":"Farlow","year":"2002","journal-title":"Int Psychogeriatr\/IPA"},{"issue":"2","key":"10.1016\/j.jns.2012.12.013_bb0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2011-110134","article-title":"Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial","volume":"26","author":"Scarpini","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jns.2012.12.013_bb0045","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","volume":"1","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.jns.2012.12.013_bb0050","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer's disease","volume":"366","author":"Howard","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jns.2012.12.013_bb0055","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2165\/11206380-000000000-00000","article-title":"Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type","volume":"71","author":"Dhillon","year":"2011","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jns.2012.12.013_bb0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline","volume":"148","author":"Raina","year":"2008","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jns.2012.12.013_bb0065","first-page":"27","article-title":"Relative tolerability of Alzheimer's disease treatments","volume":"5","author":"Alva","year":"2008","journal-title":"Psychiatry (Edgmont)"},{"issue":"4791","key":"10.1016\/j.jns.2012.12.013_bb0070","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1126\/science.3810169","article-title":"Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease","volume":"235","author":"Goldgaber","year":"1987","journal-title":"Science"},{"issue":"6106","key":"10.1016\/j.jns.2012.12.013_bb0075","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/325733a0","article-title":"The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor","volume":"325","author":"Kang","year":"1987","journal-title":"Nature"},{"issue":"4791","key":"10.1016\/j.jns.2012.12.013_bb0080","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1126\/science.2949367","article-title":"Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus","volume":"235","author":"Tanzi","year":"1987","journal-title":"Science"},{"issue":"1\u20132","key":"10.1016\/j.jns.2012.12.013_bb0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/JMN:23:1-2:105","article-title":"BACE1: the beta-secretase enzyme in Alzheimer's disease","volume":"23","author":"Vassar","year":"2004","journal-title":"J Mol Neurosci"},{"issue":"3","key":"10.1016\/j.jns.2012.12.013_bb0090","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jnr.10737","article-title":"ADAMs family members as amyloid precursor protein alpha-secretases","volume":"74","author":"Allinson","year":"2003","journal-title":"J Neurosci Res"},{"issue":"5","key":"10.1016\/j.jns.2012.12.013_bb0095","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncb960","article-title":"Reconstitution of gamma-secretase activity","volume":"5","author":"Edbauer","year":"2003","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jns.2012.12.013_bb0100","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1038\/nm1065","article-title":"Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration","volume":"10","author":"Koo","year":"2004","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jns.2012.12.013_bb0105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0006-8993(96)00609-9","article-title":"The amyloid precursor protein of Alzheimer's disease is found on the surface of static but not activity motile portions of neurites","volume":"735","author":"Storey","year":"1996","journal-title":"Brain Res"},{"issue":"8","key":"10.1016\/j.jns.2012.12.013_bb0110","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.0308655100","article-title":"Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage","volume":"101","author":"Ho","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jns.2012.12.013_bb0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jns.2012.12.013_bb0120","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of A\u03b2 immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2012.12.013_bb0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000090368","article-title":"Clinical observations with AN1792 using TAPIR analyses","volume":"2","author":"Hock","year":"2005","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.jns.2012.12.013_bb0130","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effect of A\u03b242 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jns.2012.12.013_bb0135","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jns.2012.12.013_bb0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","article-title":"Neuropathology and pathogenesis of encephalitis following amyloid \u03b2 immunization in Alzheimer's disease","volume":"14","author":"Ferrer","year":"2004","journal-title":"Brain Pathol"},{"issue":"3","key":"10.1016\/j.jns.2012.12.013_bb0145","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI200318104","article-title":"Increased T cell reactivity to amyloid \u03b2 protein in older humans and patients with Alzheimer disease","volume":"112","author":"Monsonego","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jns.2012.12.013_bb0150","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jns.2012.12.013_bb0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer's disease","volume":"8","author":"Farlow","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jns.2012.12.013_bb0160","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","article-title":"18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease","volume":"30","author":"Relkin","year":"2009","journal-title":"Neurobiol Aging"},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2012.12.013_bb0165","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2249.2009.04025.x","article-title":"Clinical applications of intravenous immunoglobulins in neurology","volume":"158","author":"Hughes","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"10.1016\/j.jns.2012.12.013_bb0170","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jns.2012.12.013_bb0175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/187152711794480438","article-title":"Alzheimer's disease: from pathogenesis to disease-modifying approaches","volume":"10","author":"Galimberti","year":"2011","journal-title":"CNS Neurol Disord Drug Targets"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X12006375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X12006375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T21:22:55Z","timestamp":1562534575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X12006375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":35,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0022510X12006375"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2012.12.013","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy against amyloid pathology in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2012.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}